

AnorMED Inc.  
Form 6-K  
January 19, 2006

OMB APPROVAL  
OMB Number:  
3235-0116  
Expires:  
July 31, 2008  
Estimated average burden  
hours per response.  
6.20

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

For the month of January 17, 2006

Commission File  
Number

**ANORMED INC.**

(Translation of registrant's name into English)

#200 - 20353 64<sup>th</sup> Avenue, Langley, British Columbia Canada V2Y 1N5

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [ ] Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Edgar Filing: AnorMED Inc. - Form 6-K

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [ ] No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ANORMED INC.**

(Registrant)

Date January 17, 2006

By

/ s / W.J. Adams

(Signature)\*

William J. (Bill) Adams, Chief  
Financial Officer

\* Print the name and title under the signature of the signing officer.

SEC 1815 (09-05) **Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

AnorMED Inc.

200 - 20353 64<sup>th</sup> Ave

**TEL** (604) 530-1057

Langley, British Columbia

**FAX** (604) 530-0976

Canada V2Y 1N5

[www.anormed.com](http://www.anormed.com)

**SHAREHOLDER ADVISES OF INTENTION TO REQUISITION SPECIAL MEETING TO CHANGE  
BOARD OF DIRECTORS**

**For Immediate Release:**

**January 17, 2006**

Vancouver, B.C. - AnorMED Inc. (TSX:AOM, AMEX:AOM) announces that Felix J. Baker and Julian C. Baker have filed a report with the U.S. Securities and Exchange Commission disclosing the intention of various entities controlled by them to requisition a special meeting of AnorMED shareholders for the purposes of replacing the Board of Directors with a new slate proposed by them. Felix Baker is a Director of AnorMED Inc.

Following the receipt of any such requisition, the Board of Directors of the Company will be meeting to discuss the requisition.

AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has a product in Phase III development, a product in Phase II development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases including HIV. Additional information on AnorMED Inc. is available on the Company's website [www.anormed.com](http://www.anormed.com).

*Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update any forward-looking statements as conditions change. Investors are referred to the discussion of the risk factors associated with the Company's business contained in the Company's Final Short Form Prospectus dated December 1, 2005 and filed with Canadian securities regulatory authorities and available on SEDAR..*

-30-

For further information:

W.J. (Bill) Adams, C.A.  
Chief Financial Officer  
Tel: (604) 530-1057  
E-mail: [info@anormed.com](mailto:info@anormed.com)

Elisabeth Whiting, M.Sc.  
VP Corporate Development & Communications  
Tel: (604) 532-4667  
E-mail : [ewhiting@anormed.com](mailto:ewhiting@anormed.com)